| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 46,715 | 46,780 | 16:11 | |
| 46,700 | 46,790 | 16:11 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 46,725 | 209 | |||
| 46,665 | 184 | |||
| 46,640 | 184 | |||
| 46,630 | 184 | |||
| 46,625 | 520 | |||
| 46,620 | 126 | |||
| 46,615 | 260 | |||
| 46,610 | 184 | |||
| 46,595 | 57 | |||
| 46,590 | 150 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 704 | 46,500 | |||
| 520 | 46,490 | |||
| 137 | 46,390 | |||
| 307 | 46,385 | |||
| 1.000 | 46,380 | |||
| 500 | 46,345 | |||
| 303 | 46,290 | |||
| 500 | 46,285 | |||
| 800 | 46,240 | |||
| 378 | 46,205 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 5.149 | 0,400 | 2.058 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:51:02 | 46,655 | 38 |
| 15:50:29 | 46,650 | 184 |
| 15:41:16 | 46,890 | 89 |
| 15:35:45 | 46,770 | 47 |
| 15:32:46 | 46,570 | 56 |
| 15:27:53 | 46,815 | 39 |
| 15:27:32 | 46,655 | 40 |
| 15:26:52 | 46,665 | 520 |
| 15:21:02 | 46,735 | 141 |
| 15:16:39 | 46,905 | 38 |
| 15:13:49 | 46,760 | 119 |
| 15:13:07 | 46,900 | 7 |
| 15:13:07 | 46,900 | 6 |
| 15:13:07 | 46,900 | 200 |
| 14:53:47 | 46,860 | 34 |
| 14:51:01 | 47,085 | 142 |
| 14:32:29 | 47,405 | 147 |
| 14:30:15 | 47,355 | 150 |
| 14:14:21 | 47,950 | 2 |
| 13:20:55 | 47,925 | 44 |
| Tagesumsatz Xetra | -2,550 -5,18 % | 3.741 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat | 85 | Seeking Alpha | ||
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Di | Moderna auf Barclays-Konferenz: Wachstumsstrategie und Pipeline-Ausbau im Fokus | 37 | Investing.com Deutsch | ||
| Di | Moderna-Aktie +6%: Wie weit geht der Höhenflug noch? | 402 | sharedeals.de | Die Moderna-Aktie zaubert seit Jahresbeginn eine atemberaubende Performance von +80% aufs Börsenparket. Zum Wochenstart legt sie um +6% auf 55,74 US$ zu. Was steckt hinter diesem Höhenflug und kann... ► Artikel lesen | |
| Mo | What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? | 36 | Benzinga.com | ||
| Fr | EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug | 661 | AFX News | PARIS (dpa-AFX) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:15 | Evotec: Eine klare Enttäuschung | 4investors | Die Analysten der Deutschen Bank bezeichnen das Strategie-Update von Evotec als enttäuschend. 2026 sollen die Umsätze noch stärker als 2025 zurückgehen. Das bereinigte EBITDA soll sich auf rund 20 Millionen... ► Artikel lesen | |
| 13:24 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update | GlobeNewswire (Europe) | $106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics'... ► Artikel lesen | |
| 13:38 | Ainos, Inc.: Water Tower Research Highlights Ainos' Scaling Momentum Across Semiconductor Value Chain | ACCESS Newswire | AI Nose deployment into front-end wafer fabrication facilities marks a critical validation step in semiconductor manufacturing environmentsRecurring revenue visibility strengthens as AI Nose deployments... ► Artikel lesen | |
| 13:36 | Oragenics, Inc.: Oragenics Initiates Phase IIa Clinical Trial Site Activation | GlobeNewswire (Europe) | FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted... ► Artikel lesen | |
| 14:09 | EQS-News: GeoVax, Inc.: GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients | EQS Group (EN) | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised... ► Artikel lesen |